Acquisition / Disposition · Results of Operations

Standard BioTools Inc. completed the sale of its aptamer-based and functional proteomics business, including SomaLogic, to Illumina, Inc. for up to $425 million in cash and royalties. This transaction marks a strategic transformation for Standard BioTools, allowing it to focus on its mass cytometry and microfluidics businesses.